10th Aug 2021 14:45
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 09 August 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 3,553,222 5.34 | 134,114 0.20 | ||||
(2) Derivatives (other than options) | 124,443 0.19 |
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 3,677,665 5.53 | 134,114 0.20 | ||||
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales | 352
1,500 500 8,300 3,950 13,719 10,400 53,564 11,100 657 700 15,769 35,730 9,527 3,611 10,065 10,900 13,200 4,500 23,112 2,000 1,095 6,990 30,725 16,911 9,918 8,482 5,443 17,803 2,100 10,296 2,933 600 12,582 4,000 4,279 8,642 2,403 24,818 2,500 9,281 1,700 1,235 4,102 4,781 10,510 7,607 19,378 2,854 13,600 | 2.4100 USD
2.3250 USD 2.3350 USD 2.3550 USD 2.3557 USD 2.3650 USD 2.4000 USD 2.4023 USD 2.4050 USD 2.4054 USD 2.4057 USD 2.4069 USD 2.4079 USD 2.4090 USD 2.4092 USD 2.4100 USD 2.4113 USD 2.4129 USD 2.4149 USD 2.4150 USD 2.4190 USD 2.4200 USD 2.4220 USD 2.4242 USD 2.4250 USD 2.4263 USD 2.4285 USD 2.4300 USD 2.4308 USD 2.4321 USD 2.4327 USD 2.4332 USD 2.4333 USD 2.4350 USD 2.4353 USD 2.4370 USD 2.4375 USD 2.4400 USD 2.4450 USD 2.4452 USD 2.4455 USD 2.4468 USD 2.4500 USD 2.4545 USD 2.4547 USD 2.4550 USD 2.4553 USD 2.4567 USD 2.4600 USD 2.4650 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other
person relating to the voting rights of any relevant securities under any option referred to on this form or relating
to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred
to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 10 August 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Related Shares:
Xeris Biopharma